Subcutaneous DMPA is an innovative injectable contraceptive that can dramatically expand access and choice for women. A new initiative led by PATH and John Snow Inc., the Subcutaneous DMPA Access Collaborative is working with ministries of health and partners across sectors to strengthen scale-up and build toward a robust global market for the product. For more information, visit http://sites.path.org/rh/?p=292.
Corporate author(s): PATH
Publication date: January 2018
768 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Global
- About PATH's work > Advancing technologies
- Health technologies > Woman-initiated protection
- Reproductive health > Family planning
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA